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Abstract
Duchenne muscular dystrophy (DMD) is a genetic disorder that causes progressive muscle weakness, ultimately leading to
early mortality in affected teenagers and young adults. Previous work from our lab has shown that a small transmembrane
protein called sarcospan (SSPN) can enhance the recruitment of adhesion complex proteins to the cell surface. When human
SSPN is expressed at three-fold levels in mdx mice, this increase in adhesion complex abundance improves muscle mem-
brane stability, preventing many of the histopathological changes associated with DMD. However, expressing higher levels of
human SSPN (ten-fold transgenic expression) causes a severe degenerative muscle phenotype in wild-type mice. Since SSPN-
mediated stabilization of the sarcolemma represents a promising therapeutic strategy in DMD, it is important to determine
whether SSPN can be introduced at high levels without toxicity. Here, we show that mouse SSPN (mSSPN) can be overex-
pressed at 30-fold levels in wild-type mice with no deleterious effects. In mdx mice, mSSPN overexpression improves dystro-
phic pathology and sarcolemmal stability. We show that these mice exhibit increased resistance to eccentric contraction-
induced damage and reduced fatigue following exercise. mSSPN overexpression improved pulmonary function and reduced
dystrophic histopathology in the diaphragm. Together, these results demonstrate that SSPN overexpression is well tolerated
in mdx mice and improves sarcolemma defects that underlie skeletal muscle and pulmonary dysfunction in DMD.
Introduction
Duchenne muscular dystrophy (DMD) is caused by mutations in
the DMD gene, resulting in loss of the dystrophin protein and its
associated protein complex, the dystrophin-glycoprotein com-
plex (DGC) (1–3). The DGC acts as a link between the
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intracellular cytoskeleton and the surrounding extracellular
matrix, providing structural stability to the sarcolemma during
muscle contraction (4–6). Although additional protein com-
plexes provide some compensatory adhesion to the extracellu-
lar matrix, the sarcolemma is susceptible to contraction-
induced damage in the absence of dystrophin and the DGC (7,8).
Over time, the progressive loss of membrane integrity leads to
cycles of muscle fibre degeneration/regeneration and ultimately
leads to muscle cell death.
In addition to the DGC, two other major adhesion complexes
are found at the muscle cell surface: the utrophin-glycoprotein
complex (UGC) and the a7b1 integrin complex (9–11). Utrophin
is a ubiquitously expressed gene that shares close homology to
dystrophin, and the composition of the UGC is largely identical
to the DGC (12,13). In non-dystrophic muscle, the UGC is largely
restricted to the postsynaptic region of neuromuscular junc-
tions. The a7b1 integrin complex provides additional linkage
and signalling between the cytoskeleton and extracellular ma-
trix (10,11). In DMD, the UGC and a7b1 integrin complexes par-
tially compensate for the absence of dystrophin by stabilizing
the sarcolemma during the mechanical stress of muscle
contraction.
SSPN is a transmembrane protein localized to the sarco-
lemma and the smallest core component of both the DGC and
UGC, and it also interacts with the a7b1 integrin complex
(14–17). Previous work from our lab has shown that overexpres-
sion of SSPN increases the cell membrane localization of all
three skeletal muscle adhesion complexes (18–20). This finding
has particular importance in the context of DMD, because nu-
merous studies have shown that the upregulation of compensa-
tory adhesion complexes can reduce or eliminate many of the
dystrophic changes that occur in the absence of dystrophin (21–
25). Previous work from our laboratory has demonstrated that
moderate overexpression of human SSPN in the mdx mouse
model of DMD increases membrane expression of the UGC and
a7b1 integrin complex, reducing markers of dystrophic pathol-
ogy and increasing membrane stability (18,19). These findings
suggest that SSPN serves as a key determinant in the expression
level of adhesion complexes at the sarcolemma, and that this
role could be leveraged as a therapeutic target in DMD.
We have previously shown that approximately three-fold
overexpression of human SSPN (hSSPN) can rescue aspects of
the mdx phenotype by increasing expression of utrophin and as-
sociated proteins throughout the extrasynaptic sarcolemma
(18,19,26). At levels of approximately 0.5 or 1.5 fold expression,
hSSPN was not able to ameliorate mdx pathology, suggesting
that a minimum three-fold level overexpression of SSPN is nec-
essary for rescue (19). However, expressing higher levels of
hSSPN in wild-type mice (ten-fold transgenic expression)
caused a severe degenerative muscle phenotype that led to pre-
mature death (27). Biochemical evidence suggests that human-
specific and mouse-specific SSPN proteins in hSSPN-Tg muscle
form insoluble aggregates of SG-SSPN complexes. This aggrega-
tion destabilizes the stability of a-DG within the DGC binding to
laminin, and leads to disorganization of the extracellular ma-
trix. It remains unclear whether the toxicity observed in hSSPN
transgenic mice is inherent to SSPN overexpression, or if it is
specific to aberrant interactions between hSSPN and endoge-
nous mouse SSPN.
Because we are pursuing genetic and pharmacological upre-
gulation of SSPN as a therapeutic avenue, it is imperative to de-
termine whether there is an upper limit of SSPN overexpression
to address concerns related to toxicity. Furthermore, the ability
of SSPN to affect skeletal and pulmonary functions has not been
reported. To directly address these questions, we generated
four lines of mice expressing multiple levels of mSSPN. In the
present study, we show that 30-fold overexpression of mSSPN
does not cause deleterious effects in muscle, and leads to a his-
tologic improvement in mdx mouse muscle that is similar to the
beneficial effect of low levels of hSSPN. We demonstrate that
mSSPN overexpression reduces membrane fragility in mdx skel-
etal muscle and improves muscle function in several different
outcome measures. Pulmonary function is improved in
mdx:mSSPN-Tg mice and the severe dystrophy associated with
the mdx diaphragm is ameliorated. These findings reveal that
high levels of SSPN overexpression in muscle are not only well
tolerated, but significantly strengthen skeletal and respiratory
parameters. Taken together, these data support the pursuit of
SSPN as a potential therapeutic target in this disease. We are
particularly encouraged that SSPN has broad applicability as an
additive treatment that is expected to boost the efficacy of all
therapies that are currently in clinical testing.
Results
mSSPN increases adhesion complexes
at the sarcolemma
We generated mSSPN transgenic mice expressing full-length
mSSPN cDNA under control of the human skeletal a-actin pro-
moter (Supplementary Material, Fig. S1A). Four independent
founder lines of mSSPN-Tg mice (lines 28, 32, 23 and 15;
Supplementary Material, Fig. S1B) were analysed for mSSPN
transgene expression, and the highest expressing line was cho-
sen for detailed analysis. Based on immunoblot analysis, this
line expresses mSSPN at approximately 30-fold over endoge-
nous levels, as determined by immunoblot (line 28;
Supplementary Material, Fig. S1C). Previous work from our lab
has shown that ten-fold transgenic expression of human SSPN
in wild-type mice leads to a severe muscle phenotype that in-
cludes muscle degeneration, kyphosis and death at 6-10 weeks
of age (27). By contrast, wild-type mice overexpressing mSSPN
are healthy, breed well, exhibit no signs of muscle pathology,
and appear to have a normal lifespan (the oldest transgenic car-
riers in our colony are currently over 2.5 years of age).
Male mSSPN-Tg mice were crossed to mdx females to gener-
ate dystrophin-deficient mice expressing transgenic mSSPN
(mdx:mSSPN-Tg). Robust expression of SSPN was detected at the
sarcolemma of all transgenic wild-type (WT) and mdx mice
(Fig. 1A and B, Supplementary Material, Fig. S1). Relative to WT
muscle, WT:mSSPN-Tg had increased sarcolemmal localization
of utrophin, dystrophin, and b1D integrin, showing that overex-
pression of mSSPN affects all three major adhesion complexes
in muscle. Similarly, mdx:mSSPN-Tg showed increased levels of
utrophin and b1D integrin at the sarcolemma. We additionally
found increased abundance of the sarcoglycans in WT and mdx
mice expressing mSSPN, although immunofluorescence did not
reveal major changes in b-dystroglycan expression at the
sarcolemma.
In order to specifically examine the abundance of adhesion
complexes associated with the sarcolemma, muscle lysates
were additionally assessed using sWGA lectin chromatography,
which binds glycoproteins with GlcNAc glycans associated with
the DGC and UGC (14). In this binding assay, protein interactions
within complexes are preserved using a mild digitonin buffer
followed by lectin binding, allowing analysis of intact adhesion
complexes. By immunoblot of sWGA-enriched samples, we
found that overexpression of mSSPN increased levels of DGC
5396 | Human Molecular Genetics, 2016, Vol. 25, No. 24
and UGC components associated with the sarcolemma (Fig. 1C).
Laminin binding to a-DG was additionally assessed by overlay-
ing laminin protein onto sWGA-enriched skeletal muscle ly-
sates, revealing an increase in mdx:mSSPN-Tg laminin binding.
Overexpression of mSSPN improves dystrophic
pathology and membrane stability in mdx mice
We next examined mdx:mSSPN-Tg muscle for changes in the
dystrophic pathology associated with the mdx phenotype. At 6
weeks, haematoxylin and eosin (H&E) stained transverse cryo-
sections of quadriceps from mdx:mSSPN-Tg mice displayed a re-
duction of degeneration and necrosis relative to mdx littermates
(Fig. 2A). Quantitative analysis of muscle cryosections also re-
vealed a significant decrease in the percentage of fibres with
central nuclei, indicating a reduction in the cycles of regenera-
tion/degeneration that are normally associated with loss of dys-
trophin (Fig. 2A and B).
In DMD, the absence of dystrophin and subsequent loss of
DGC-associated proteins at the sarcolemma leads to membrane
instability and vulnerability to contraction-induced damage
(7,8). To determine whether mSSPN expression decreases sarco-
lemmal disruption in mdx mice, we performed an in vivo tracer
assay with Evans blue dye (EBD). EBD binds to albumin in blood
serum, and accumulates in damaged and permeable muscle
fibres (28). mdx mice displayed a high level of muscle fibres
marked by EBD accumulation (Fig. 2C and D). Quads from
mdx:mSSPN-Tg mice had significantly decreased EBD-positive
fibres relative to mdx mice and were not significantly different
from WT, demonstrating that mSSPN overexpression at levels
as high as 30-fold improves sarcolemmal stability. To further
examine the role of SSPN in stabilizing the sarcolemma, we
tested serum creatine kinase (CK) levels in mdx mice, WT, and
mdx:mSSPN-Tg mice at 6 months (Fig. 2E). Muscle damage and
degeneration leads to elevated CK levels throughout the mdx
lifespan. mSSPN-Tg overexpression significantly decreased se-
rum creatine kinase levels relative to mdx mice, showing that
mSSPN overexpression reduces sarcolemmal damage and leak-
age in mdx mice.
Transgenic mSSPN expression improves muscle
strength and function in mdx mice
In order to investigate the effect of mSSPN transgene expression
on muscle strength, forelimb grip strength was tested at 6
weeks (Fig. 3A). Grip strength provides a simple method to mea-
sure mouse forelimb strength in vivo. We performed five consec-
utive trials on each mouse five times, and found that mdx mice
were significantly weaker by the fifth trial. In mdx mice overex-
pressing mSSPN, grip strength was significantly increased rela-
tive to mdx littermates.
During grip strength testing, we observed that mdx:mSSPN-Tg
mice appeared more active than mdx littermates following the
relatively mild exertion of the grip strength protocol. Based on
Figure 1. mSSPN can be highly expressed without toxicity and can restore some components of major muscle adhesion complexes. Transverse sections of WT,
WT:mSSPN-Tg, (A) mdx and mdx:mSSPN-Tg (B) quadriceps were stained with antibodies against components of the three major muscle adhesion complexes. Bar,
100 mm. (C) Skeletal muscle lysates from mdx and mdx:mSSPN-Tg were solubilized using digitonin and enriched using sWGA lectin chromatography. Eluates were re-
solved by SDS–PAGE and immunoblotted with indicated antibodies. Laminin overlay onto a-DG is also shown (lam O/L).
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this observation, we used an open field assay to test voluntary ac-
tivity after exercise. Immediately following grip strength testing,
6-month-old mice were placed in a novel chamber and allowed to
freely explore for 6 minutes. Animal activity was video recorded,
and the position of the mouse was tracked over the testing period
(Fig. 3B). While mdx mice moved very little during the 6 minutes
following grip strength exercise, the voluntary activity of
mdx:mSSPN-Tg littermates was significantly increased through-
out the trial (Fig. 3C). Surprisingly, expression of the mSSPN trans-
gene completely restored mdx activity to wild-type levels, as there
was no significant difference between mdx:mSSPN-Tg and WT
control activity post-exercise. When the mice were not chal-
lenged with a mild exercise protocol, there was no significant dif-
ference in distance travelled between WT, mdx and mdx:mSSPN-
Tg mice (Supplementary Material, Fig. S2A and B).
Given the substantial improvement in mdx:mSSPN-Tg post-
exercise activity, we tested nNOS levels in WT, mdx and
mdx:mSSPN-Tg muscle to determine if mSSPN overexpression
altered nNOS localization or abundance. nNOS is a component
of the DGC and regulates vasorelaxation via the production of
nitric oxide (29). In the absence of dystrophin, nNOS is lost from
the sarcolemma and directly contributes to exercise-related fa-
tigue in DMD (30,31). Although the mSSPN transgene restored
post-exercise activity in mdx, we did not see any restoration of
nNOS to the sarcolemma or increase in overall nNOS abundance
(Supplementary Material, Fig. S2C and D).
Muscle physiology was tested on extensor digitorum longus
(EDL) muscles isolated from WT, mdx and mdx:mSSPN-Tg mice
at 5 months of age. EDL from mdx had a 25% decrease in specific
force production relative to WT EDL (Fig. 3D). Overexpression of
Figure 2. mSSPN overexpression greatly improves muscle histology and membrane stability in mdx mice. (A) Transverse sections of quadriceps muscle from 6 week old
mdx and mdx:mSSPN-Tg mice were stained with H&E to visualize muscle pathology. Bar, 100 mm. (B) Sections from mdx:mSSPN-Tg quadriceps display reduced central
nucleation relative to mdx muscle (WT, n¼6, mdx n¼6, mdx:mSSPN-Tg n¼4). (C&D) Quad sections from 6-week-old Evans Blue Dye (EBD)-injected mdx:mSSPN-Tg and
mdx mice were stained with antibody against laminin (green) to delineate the sarcolemma. EBD-positive fibres were visualized by red fluorescence, which serves as a
marker for membrane damage (WT n¼ 4, mdx n¼ 6, mdx:mSSPN-Tg n¼6). Bar, 100 mm. (E) Creatine kinase levels from serum were measured at 20 weeks of age (mdx
n¼4, mdx:mSSPN-Tg n¼ 8, WT¼6). Data represent means6 SEM. Statistics calculated using one-way ANOVA followed by Tukey’s multiple comparison’s test (*P<0.05,
**P< 0.01, ***P<0.001 and ****P<0.0001).
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mSSPN did not improve specific force production, as there was
no significant difference between mdx and mdx:mSSPN-Tg EDL
(Fig. 3D). However, mdx:mSSPN-Tg EDL showed marked resis-
tance to a series of eccentric contractions when compared to
mdx EDL. While repeated eccentric contractions resulted in a
large loss of force in the isolated mdx muscle, mdx:mSSPN-Tg
muscle maintained a force output similar to WT during the pro-
tocol (Fig. 3E).
Expression of mSSPN reduces dystrophy in
mdx diaphragm
As with other mouse models of muscular dystrophy, mdx mice
have unusually thickened diaphragms at an early age (32–34).
Upon dissection, we noted that diaphragms from mdx:mSSPN-
Tg mice appeared thinner and less fibrotic than those of mdx lit-
termates. In order to quantify this thickness relative to WT
diaphragms, sections were taken from the anterolateral right
costal muscle in WT, mdx and mdx:mSSPN-Tg mice at 6 weeks
of age (Fig. 4A). We found that the expression of the mSSPN
transgene reduced mdx diaphragm thickness to that of WT
diaphragms (Fig. 4B). Similar to quadriceps, the number of fibres
with centralized nuclei was also decreased in mdx:SSPN-Tg dia-
phragm (Fig. 4C and D). To determine whether mSSPN expres-
sion improves sarcolemmal stabilization in mdx diaphragm
fibres, we additionally evaluated EBD uptake in the diaphragm
(Fig. 4E and F). Diaphragms from 6-week-old mdx:mSSPN-Tg
mice had a significant reduction in the number of positive EBD
fibres relative to mdx, demonstrating that SSPN significantly re-
duces sarcolemmal susceptibility to injury.
SSPN improves pulmonary function in mdx mice
In most individuals with DMD, progressive weakness of respira-
tory muscles leads to pulmonary dysfunction and contributes
to early mortality (35). In light of the changes seen in the
mdx:SSPN-Tg diaphragm, a major respiratory muscle, we further
assessed the effect of the mSSPN transgene on mdx pulmonary
function. We found that mSSPN transgene expression was pre-
sent in accessory respiratory muscles at levels comparable to
limb muscle, and also expressed at lower levels in the heart
(Fig. 5A). We monitored respiratory parameters in mice at 26
Figure 3. Transgenic expression of mSSPN improves muscle physiology in mdx mice. (A) Forelimb grip strength normalized to body weight at 6 weeks of age (fifth con-
secutive trial reported). (B) Representative traces of mouse activity in an open field during a 6 minute recording time. (C) Post-exercise walking distances at 6 months of
age were recorded using an open field activity chamber (n¼4 for mdx, n¼5 for mdx:mSSPN-Tg and WT). (D) Specific force measurement in transgenic mice. (E) Force pro-
duction in EDL as a percent of initial force, following a series of eccentric contractions (n¼6 for all groups). Data represent means6 SEM. Statistics calculated using one-
way ANOVA followed by Tukey’s multiple comparison’s test (A,D) or two-way ANOVA (C,E) (*P < 0.05, **P < 0.01 and ****P < 0.0001).
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weeks of age using whole-body plethysmography. Ventilation
was measured at rest and during hypercapnic challenges as de-
scribed by Capote and colleagues (36). None of the respiratory
parameters tested were significantly different between WT and
mdx mice during baseline room air conditions (Supplementary
Material, Table S1). During the first hypercapnic challenge, mea-
sures of minute ventilation, respiratory frequency, peak inspira-
tory flow (PIF) and peak expiratory flow (PEF) were all
significantly decreased in mdx mice relative to WT controls (Fig.
5A–D). Of these parameters, mdx:mSSPN-Tg mice showed signif-
icant improvements in minute ventilation and PEF relative to
mdx mice (Fig. 5B and E), and no change in frequency or PIF (Fig.
5C and D).
In order to further evaluate the role of SSPN in maintaining
respiratory muscle integrity, we assessed pulmonary function
in mice lacking SSPN (SSPN-null). While lacking an overt dystro-
phic muscle phenotype at a young age (37), SSPN-null mice ex-
hibit age-dependent skeletal and cardiac muscle pathology
(16,26). No pulmonary deficits have previously been reported in
this model. We tested the mice using whole-body plethysmog-
raphy at 42 weeks of age at room air and during hypercapnic
challenges. At baseline, minute ventilation, respiratory fre-
quency and PIF were significantly decreased in SSPN-null mice
relative to WT (Supplementary Material, Table S2). During the
first hypercapnic challenge, both PIF and PEF were significantly
decreased in SSPN-null mice relative to WT (Fig. 5F and G).
Figure 4. Diaphragms from mdx:mSSPN-Tg have reduced dystrophic pathology. (A&B) Transverse sections of diaphragm muscle from 6 week old mdx and mdx:mSSPN-
Tg mice were stained with H&E to visualize muscle pathology. The average thickness of the diaphragm is shown (WT n¼4, mdx n¼3, mdx:mSSPN-Tg n¼3, P <0.0001).
Bar, 100 mm. (C&D) Sections were stained with H&E and Masson’s trichrome (MT) to visualize muscle pathology. Bar, 200 mm. Fibres from mdx:mSSPN-Tg diaphragm ex-
hibit reduced central nucleation (n¼3 for all conditions). (E&F) Diaphragm sections from 6-week old Evans Blue Dye (EBD)-injected mdx:mSSPN-Tg show reduced EBD
positive fibres compared with mdx, indicating an improvement in membrane stability. Statistics calculated using one-way ANOVA followed by Tukey’s multiple com-
parison’s test (B&D) or Student’s t-test (F). Data represent means6 SEM. Statistics calculated using one-way ANOVA followed by Tukey’s multiple comparison’s test (B)
or two-way ANOVA (D) (*P < 0.05, ***P < 0.001 and ****P < 0.0001).
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Interestingly, although PIF was decreased in SSPN-null mice,
overexpression of mSSPN-Tg failed to rescue PIF in the mdx
model, suggesting that dystrophin and sarcospan deficiencies
cause distinct patterns of respiratory defects.
Discussion
Membrane damage is one of the earliest cellular events in the
pathogenesis of DMD. In this study, we show that mSSPN over-
expression reduces membrane damage in mdx mouse muscle,
leading to overall reduced dystrophic pathology. These findings
support the pursuit of SSPN upregulation as a therapeutic ave-
nue for DMD and demonstrate that even very high levels of
SSPN overexpression are not toxic in muscle. Similar to our pre-
vious studies of hSSPN overexpression in mdx and WT mouse
muscle, our results show mSSPN increases localization of cer-
tain adhesion complex components at the sarcolemma.
However, this increase is modest, suggesting that SSPN-
mediated stabilization of the sarcolemma can occur through
relatively low levels of adhesion complex upregulation. The
Figure 5. SSPN expression improves pulmonary function in mdx mice. (A) Transverse sections of the diaphragm, abdominal, intercostal and heart from were stained
with antibody against SPPN in order to determine the relative SSPN expression in muscles associated with pulmonary function. Sections from quadriceps are shown
for comparison. (B–E) The pulmonary function of age-matched WT, mdx and mdx:mSSPN-Tg mice was measured using whole-body plethysmography. Reported mea-
surements were recorded during first hypercapnic challenge: minute ventilation (B), frequency (C), peak inspiratory flow (D), and peak expiratory flow (E). (F,G) To eval-
uate the effect of loss of SSPN on pulmonary function, age-matched WT and SSPN-null mice were also tested. Both peak inspiratory flow (F) and peak expiratory flow
(G) were significantly decreased in SSPN-null mice. Data represent means6 SEM. Statistics calculated using one-way ANOVA followed by Tukey’s multiple compari-
son’s test (B-E) or Student’s t-test (F-G) (*P < 0.05, **P < 0.01, ***P < 0.001 and ****P <0.0001).
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SSPN-mediated increase in adhesion complex localization leads
to substantial improvement in the histopathological features of
mdx muscle, consistent with previous studies from our labora-
tory. We additionally find that membrane stability, one of the
earliest cellular events in the pathogenesis of DMD, is signifi-
cantly ameliorated in mdx by the overexpression of mSSPN, as
assessed by serum CK level and EBD tracer assay.
Here, we also show that SSPN overexpression ameliorates
skeletal muscle some physiological deficits in mdx mice. Based
on histological findings, we used several approaches to assess
muscle function in mdx:mSSPN-Tg mice. While in vitro measure-
ment of mdx:mSSPN-Tg EDL showed no improvement in force
generation relative to mdx, the mSSPN transgene conferred sub-
stantial protection against eccentric contraction-induced dam-
age. The susceptibility of mdx muscle to eccentric contraction is
directly related to membrane integrity; force drop is thus
viewed as an index of membrane fragility (38). Together with
the improvements seen in the serum CK level and the EBD
tracer assay, these findings demonstrate that SSPN overexpres-
sion has a substantial effect on membrane stability, and can
help counter the progressive degeneration associated with dys-
trophin loss (Fig. 6A-B).
Previous studies have shown that voluntary activity in mdx
mice is dramatically reduced following mild exercise protocols
(30,39). During grip strength testing of mdx and mdx:mSSPN-Tg
littermates, we noticed that while mdx mice appeared fatigued
and lethargic immediately following testing, mice carrying the
mSSPN transgene remained active and alert. When we formally
tested this observation using an open field activity assay, we
consistently found that mdx:mSSPN-Tg mice were as active as
WT mice following the mild exertion of the grip strength proto-
col. This is particularly interesting in light of our grip strength
findings: although mdx:mSSPN-Tg were able to exert approxi-
mately twice as much force in terms of repeated grip strength
measures, the force was still far less than that of WT. Together
with our in vitro data, these findings suggest that SSPN-
mediated stabilization of the mdx sarcolemma ameliorates spe-
cific aspects of dystrophic physiology, and may improve
fatigue-like properties while having minimal impact on overall
muscle strength.
Diaphragm is one of the most affected muscles throughout
the lifespan of the mdx, displaying a higher degree of fibrosis
and fat infiltration than other skeletal muscles. We found that
mSSPN overexpression substantially improves pathology of the
diaphragm in mdx mice. Given that diaphragm is one of the ma-
jor respiratory muscles, we evaluated pulmonary function in
mdx and mdx:mSSPN-Tg mice. Previous studies have found
varying degrees of change in mdx ventilation, but generally sug-
gest that loss of dystrophin in mice leads to modest, age-
dependent deficits in pulmonary function (33,40,41). In compar-
ing mdx respiration to that of WT at approximately 6 months of
age, we found that hypercapnic challenge induced significant
changes in most respiratory parameters, although there was lit-
tle difference during room air measurements. Expression of
mSSPN improved several measurements in mdx, including MV
and PEF. Surprisingly, PIF was not improved by mSSPN expres-
sion, although this measurement is thought to be particularly
sensitive to diaphragm function. In order to better understand
the role of SSPN in this highly active muscle, we additionally
tested pulmonary function in WT and SSPN-null mice.
Although loss of SSPN does not lead to a severe dystrophic mus-
cle phenotype, we previously showed that the SSPN-null dia-
phragm is more vulnerable to eccentric contraction damage and
generates reduced specific force (16). Consistent with these
Figure 6. Schematic summarizing mSSPN transgenic overexpression in mdx muscle. The underlying deficit in DMD and related muscular dystrophies is the loss of pro-
tective connections between the sarcolemma and the extracellular matrix (ECM). Within the DGC and UGC, the dystroglycans link the membrane complex to laminin.
In mdx muscle, the DGC is absent and leads to increased contraction-induced membrane damage. When mSSPN is overexpressed in mdx muscle, laminin binding is in-
creased and sarcolemmal stability is enhanced. This increase in sarcolemmal stability leads to reduced muscle degeneration over time.
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findings, we found that both PIF and PEF are significantly de-
creased in SSPN-null mice relative to WT. These results are con-
sistent with a key role for SSPN in maintaining sarcolemmal
stability both in healthy and dystrophic muscle.
Our results, combined with previous findings from our labo-
ratory, indicate that SSPN supports sarcolemmal stability in
skeletal muscle through interaction with adhesion complexes.
In the absence of dystrophin, this protective role prevents mem-
brane damage and improves muscle physiology and pulmonary
function. Many treatments currently in development for DMD
are targeted at restoring the sarcolemmal connection to the ex-
tracellular matrix. The goal of these therapies is to increase
membrane stability through either the direct replacement/res-
toration of dystrophin or the upregulation of other adhesion
complex proteins. One major challenge in all of these potential
treatments will be establishing enough protein at the cell mem-
brane surface to produce a therapeutic effect (42). In light of
these emerging therapies, identifying pathways that can en-
hance membrane localization of adhesion complexes and in-
crease membrane stability is particularly important. SSPN is
attractive as a potential therapeutic target, since it plays a direct
role in stabilizing the sarcolemma, and additionally could serve
to enhance localization of other adhesion complex proteins.
This strategy is particularly appealing because it could also be
used to augment other drug and gene therapies currently in
development.
Materials and Methods
Animals
Wild-type (C57BL/6J) and mdx mice (C57Bl/10ScSn background)
were purchased from Jackson Laboratories (Bar Harbor, ME,
USA). SSPN-null mice were a generous gift from Dr. Kevin P.
Campbell (University of Iowa Carver College of Medicine, Iowa
City, IA) (37). Transgenic constructs were designed with the hu-
man skeletal actin promoter and VP1 intron upstream of the
full-length mouse SSPN cDNA, as described previously (27,43).
Transgenic mice were generated by microinjection of transgenic
constructs into the pronucleus of fertilized single-cell embryos
(C57BL/6J background, Transgenic Mouse Facility, University of
California, Irvine), and four viable lines were recovered (Lines
28, 23, 32 and 15). Transgenic lines were maintained on a C57BL/
6J background.
Males from each transgenic line were crossed to mdx females
to generate transgenic mdx lines and maintained by sibling
crosses (B6/B10ScSn background). Mice were maintained in the
Terasaki Life Sciences Vivarium following guidelines estab-
lished by the Institutional Animal Care and Use Committee at
the University of California, Los Angeles (approval #2000-029-
43) and approval for these studies was granted by the UCLA
Animal Welfare Assurance (approval #A3196-01). All mice used
in the study were male.
Skeletal muscle protein preparation
Prior to dissection, mice were euthanized using isoflurane. The
total skeletal muscle was snap frozen in liquid nitrogen and
stored at80 C. Tissues were ground to a fine powder using a
liquid nitrogen-cooled mortar and pestle, added to ice-cold ho-
mogenization buffer and homogenized in radioimmunoprecipi-
tation assay buffer (RIPA; Thermo Fisher Scientific) with
protease inhibitors (0.6 mg/ml pepstatin A, 0.5 mg/ml aprotinin,
0.5 mg/ml leupeptin, 0.75 mM benzamidine, 0.2 mM PMSF, 5 mM
calpain I, and 5 mM calpeptin). Homogenates were rotated at 4 C
for 1 h and clarified by centrifugation at 15,000 rpm for 20 min at
4 C. Protein concentration was determined using the DC
Protein Assay (Bio-Rad Laboratories), and lysates were stored at
-80 C.
sWGA enrichment
Sarcolemmal-associated a-DG complexes were enriched as pre-
viously described (16). Briefly, lysates from mdx and
mdx:mSSPN-Tg was solubilized using 1% digitonin in homogeni-
zation buffer, and equal protein concentrations of clarified ly-
sates were applied to succinylated wheat germ agglutinin
(sWGA)-conjugated agarose beads (AL-1023S; Vector laborato-
ries). Bound proteins were subsequently eluted from the col-
umn with N-acetyl glucosamine (Sigma-Aldrich). Equal
concentrations of eluates (10 mg) were resolved by SDS-PAGE
and analysed as described below.
Immunoblot analysis
Equal quantities of protein samples were resolved on 4-20% pre-
cise protein gels by SDS-PAGE (4-20% Precise Protein Gels,
Thermo Fisher Scientific) and transferred to nitrocellulose
membrane (Millipore). Membranes were blocked for 1 hour in
5% nonfat dry milk in TBS with 0.2% Tween 20 and incubate in
primary antibodies overnight at 4 C. Incubations were per-
formed with the following primary antibodies: dystrophin
(MANDYS1; 1:5), utrophin (MANCHO3; 1:50), a-DG IIH6 (sc-53987;
1:500; Santa Cruz Biotechnology, Inc.), b-DG (MANDAG2; 1:250),
a-SG (VP-A105; 1:100), b-SG (VP-B206; 1:100), c-SG (VP-G803;
1:100), nNOS (A-11, 1:250; Santa Cruz), laminin (L9393; 1:5,000),
b1D integrin (MAB1900; 1:100), GAPDH (MAB374, 1:50,000;
Chemicon) and SSPN (E2; 1:500; Santa Cruz). Horseradish
peroxidase–conjugated anti–rabbit IgG and anti–mouse IgG (GE
Healthcare) secondary antibodies were used at 1:2,000 dilutions
in 5% nonfat dry milk and incubated at RT for 3 h. Immunoblots
were developed using enhanced chemiluminescence
(SuperSignal West Pico Chemiluminescent Substrate; Thermo
Fisher Scientific). Mean integrated density value was quantified
using ImageJ (NIH).
Laminin overlay assay
Membranes were prepared as described in sWGA enrichment of
protein lysates. Membranes were blocked with 5% BSA in
laminin-binding buffer (10 mM triethanolamine, 140 mM NaCl,
1 mM MgCl2, and 1 mM CaCl2, pH 7.6) followed by incubation of
Engelbreth-Holm-Swarm laminin (354239; BD) in laminin-
binding buffer for 8 h at 4 C. Membranes were washed and in-
cubated with rabbit anti-laminin antibody (L9393; 1:5,000;
Sigma-Aldrich) overnight at 4 C. Blots were probed with sec-
ondary and developed as described above.
Immunohistochemistry
Muscles were mounted in OCT (Tissue-Tek) and flash frozen in
liquid nitrogen–cooled isopentane, and stored at 80 C until
further processing. Transverse 7-mm transverse cryosections
were blocked with 3% BSA in PBS for 30 min at room tempera-
ture. Avidin/biotin blocking kit (Vector Laboratories) was used
according to manufacturer’s instructions. For antibodies raised
in mouse, Mouse on Mouse blocking reagent (Vector
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Laboratories) was used according to manufacturer’s instruc-
tions. Sections were incubated in primary antibody in PBS at
4 C overnight with the following antibodies: dystrophin
(MANDYS1; 1:5; Development Studies Hybridoma Bank), utro-
phin (DRP, 1:100), b-DG (MANDAG2; 1:50; Development Studies
Hybridoma Bank), a-SG (VP-A105; 1:30; Vector Laboratories),
b-SG (VP-B206; 1:30; Vector Laboratories), a7 integrin (C-20;
1:100; Santa Cruz), nNOS (A-11, 1:250; Santa Cruz), laminin
(L9393; 1:500; Sigma-Aldrich), b1D integrin (MAB1900; 1:20;
Millipore), and SSPN (E2; 1:100). Primary antibodies were de-
tected by biotinylated anti–rabbit (BA-1000; 1:500; Vector
Laboratories) and biotinylated anti–mouse (BA-9200; 1:500;
Vector Laboratories). Fluorescein–conjugated avidin D (A-2001;
1:500; Vector Laboratories) was used to detect secondary anti-
bodies and biotinylated WFA. All sections were mounted in
Vectashield (Vector Laboratories) and visualized using an
Axioplan 2 fluorescence microscope with Axiovision 3.0 soft-
ware (Carl Zeiss Inc, Thornwood, NY, USA).
Histology
To assess general muscle pathology, transverse sections from
the quadriceps, tibialis anterior, EDL, heart, intercostal, abdomi-
nal and diaphragm muscles (8 lm) were stained with H&E as de-
scribed previously (16). The percentage of centrally nucleated
fibres was assessed for quadriceps and diaphragm muscle from
6-week-old animals.
Evans blue dye assay
Evans blue dye (EBD) was diluted in PBS to a final concentration
of 10 mg/ml and was sterilized by filtration using a 0.2 lm filter.
EBD was administered by intraperitoneal injection 10-12 hours
before dissection (50 ll of diluted EBD per 10 g of body weight).
Quadriceps and diaphragms were processed as described above,
counterstained with antibody against laminin, and visualized
using fluorescence microscopy. The percentage of EBD-positive
fibres was obtained by counting the number of EBD-positive
fibres in a quadriceps or diaphragm section and dividing by the
total number of myofibres.
Grip strength test
Forelimb grip strength was measured using a digital force gauge
(Columbus Instruments, Columbus, OH). In each trial, the
mouse grasped the pull bar connected to the grip strength me-
ter and was gently pulled back until the pull bar was released.
This procedure was repeated five times per trial and peak ten-
sion (N) was recorded for each trial. Five trials were performed
with 1 min of rest between each trial. Fifth trial peak tension
values normalized to body weight (N/g) are reported.
Open field activity
Post-exercise ambulation in 6-month-old animals was recorded
immediately following grip strength testing. Mice were placed
in individual recording chambers and allowed to roam freely for
6 minutes. The distance travelled by each animal was
determined using frame-by-frame object tracking in Kinovea
open source video analysis software (Version 0.8.15, http://
www.kinovea.org; date last accessed October 21, 2016).
Serum creatine kinase assay
Blood was collected from the retro-orbital sinus of 6-month-old
WT, mdx and mdx:mSSPN-Tg mice. Total serum creatine kinase
(CK) levels were measured with a Beckman Coulter UV
spectrometer (Fullerton, CA) using a creatine kinase reagent
(CK-NAC; Teco diagnostics, Anaheim, CA) according to the man-
ufacturer’s instructions.
Mouse muscle physiology
The contractile properties of the EDL were measured as de-
scribed previously by the muscle phenotyping core facility at
the University of Pennsylvania (Dr. Elisabeth R. Barton,
University of Pennsylvania, Philadelphia, PA) (16). Muscles were
dissected, removed and placed in a bath of Ringer’s solution
gas-equilibrated with 95% O2/5% CO2. Muscles were subjected to
isolated mechanical measurements. After determining the opti-
mum length (Lo) by supramaximal twitch stimulation, maxi-
mum isometric tetanus was measured. Muscles were then
subjected to a series of five eccentric contractions with a 5 min
rest between contractions.
Whole body plethysmography
Pulmonary function was measured as previously described (36).
Briefly, respiration was monitored in conscious, unrestrained
mice using a whole body plethysmography apparatus (Buxco
Research Systems). Mice were acclimatized in monitoring
chambers for 1 hour at room air conditions (RA). Baseline mea-
surements were recorded during the final 5 min of acclimatiza-
tion. The mice were then exposed to hypercapnic conditions
(8% CO2/21% O2/balance N2) and then returned to RA for 10 min.
Following RA conditions, mice were exposed to a second hyper-
capnic challenge. Data from the first hypercapnic challenge are
included in Fig. 5; all pulmonary measurements are reported in
Supplementary Materials, Tables S1 and S2.
Supplementary Material
Supplementary Material is available at HMG online.
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